SUMMARY Administration of isaxonine (6 mg/kg powdered diet) had no effect on regeneration following sciatic nerve crush in the rat. In 10 patients undergoing treatment with vincristine (1*4 mg/m2 twice monthly) development of peripheral neuropathy was quantitated by neurological symptoms, signs and electrophysiological tests. Five also received isaxonine (1-5 g daily). All patients developed evidence of neuropathy, but in none was it severe. The three lowest disability scores were obtained in isaxonine treated patients, but the highest score was also in an isaxonine treated patient. The equivocal findings in this small study could not be amplified because the drug was withdrawn from clinical use on account of its hepatotoxicity.
The clinical use of isaxonine (N-isopropyl-amino-2-pyrimidine orthophosphate) was initiated by the experimental findings that the drug promoted sprouting of neurites in cultured mouse spinal ganglia, ' and enhanced the mean regeneration rate of peripheral nerve following cold injury from 1-6 to 2*3 mm per day.2 A number of clinical trials, some double blind,-on relatively small numbers of patients with diabetic neuropathy,3 Bell's palsy,4 and vincristine induced neuropathy,56 suggested that isaxonine was beneficial in the prevention or treatment of peripheral nerve disease.
Between 1978 and 1982, more than 150 000 patients in France were treated with isaxonine. It then became apparent that hepatitis developed in 28 per 100 000 individuals receiving the drug, and it was withdrawn from clinical use. This occurred prior to the completion of a small double blind controlled trial of isaxonine in patients receiving vincristine in the UK. This paper reports the results of this trial, and also those of a study of the effects of the drug on peripheral nerve regeneration after crush in the rat.
Methods and results

Experimental study
The sciatic nerve was crushed in the thigh of 10 Sprague Dawley rats using smooth tipped watchmakers forceps applied for 10 seconds. Five animals acted as controls. One was fed a powdered diet containing 6 g/kg isaxonine (giving a daily intake of approximately 300 mg/kg body weight), and the other four received isaxonine 150 mg/kg by intraperitoneal injection five times per week from the time of crush. Serial measurements were made of amplitude and latency of the muscle action potential recorded from the first interosseus muscle through intracutaneous clip electrodes following nerve stimulation at the ankle and upper thigh at the following intervals: before crush; weekly from 3-8 weeks; every two weeks from [8] [9] [10] [11] [12] weeks; and every four weeks until the experiment terminated after 16-28 weeks. Two of the treated animals died, one as a result of intraperitoneal haemorrhage following injection, and the other for no obvious cause at 16 weeks.
There were no differences between the treated and untreated animals in the time of earliest detectable reinnervation (4/5 controls and 3/5 treated animals at four 933 934 Le Quesne, Fowler, Harding The effects of isaxonine on vincristine-induced neuropathy symptoms. Vibration sense was depressed at the toes in some subjects. Five patients (three placebo and two isaxonine) developed mild weakness of finger and/or wrist extension.
Cumulative scores during the trial are shown in the figure. Four out of the five cases in the treated group had consistently lower scores than those given placebo, but the difference between the two groups was not significant at the 5% level using Wilcoxon's rank sum test. The older patients had higher scores than all the younger patients except one in the treated group who scored particularly highly. There was no apparent reason for the development of severe neuropathy in this patient, who assumes importance in view of the small numbers, and it was thought that compliance was good. Discussion
In contrast to the enhanced regeneration of peripheral nerve observed by Hugelin and 
